原研机构 |
在研机构- |
非在研机构 |
最高研发阶段无进展临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
开始日期2016-03-01 |
申办/合作机构 |
开始日期2014-09-01 |
申办/合作机构 |
开始日期2012-10-01 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
乙型肝炎 | 临床2期 | 摩尔多瓦 | 2014-09-01 | |
丁型肝炎 | 临床2期 | 摩尔多瓦 | 2014-09-01 | |
慢性乙型肝炎 | 临床2期 | - | 2012-10-01 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | 3 | 襯選淵醖餘選選壓鏇齋(範鹹鬱糧夢醖餘獵積鹽) = No significant adverse events (including ALT elevation) have been observed to date 構衊簾艱積顧窪夢鏇夢 (範膚艱遞鏇簾顧壓鑰獵 ) | - | 2023-11-10 | |||
临床2期 | 40 | 築獵襯糧網網顧衊簾餘(艱繭鬱夢淵繭鬱製鬱衊) = PegIFN-induced thrombocytopenia (P = .299 vs controls) and neutropenia (P = .112 vs controls) were unaffected by NAPs (REP 2139 vs REP 2165). Increases in levels of transaminases were significantly more frequent (P < .001 vs controls) and greater (P = .002 vs controls) in the NAP groups (but did not produce symptoms), correlated with initial decrease in HBsAg, and normalized during therapy and follow-up. 網窪觸鏇壓蓋淵夢廠鹹 (鹽構鏇淵鬱網蓋壓鹽鬱 ) 更多 | 积极 | 2020-03-06 | |||
临床1/2期 | 12 | 鹽鑰製鏇夢製築鹽艱鹹(網選築壓憲鹽蓋衊夢製) = 簾選餘遞衊簾獵蓋願選 鹹遞獵繭願範糧鬱壓獵 (鏇鬱窪齋醖鹽積餘膚鹹 ) 更多 | - | 2019-12-01 | |||
临床2期 | 5 | 窪鹽齋膚窪夢齋築鹹顧(繭衊夢選構選鹽鹽鑰壓) = 鬱鏇願餘範選膚憲憲艱 觸糧願網鏇顧繭窪膚築 (窪糧醖網構遞壓廠繭鏇, 鏇構鹹窪襯壓襯積蓋膚 ~ 願衊壓鏇衊壓鹹齋鹽憲) 更多 | - | 2019-05-08 | |||
临床2期 | 12 | REP 2139+pegylated interferon alfa-2a | 願網夢鏇鑰壓獵鬱艱簾(餘衊築夢鏇衊觸窪鏇鬱) = 範網觸願遞範鹽窪鹹觸 鬱鏇鏇積糧廠獵齋壓製 (範鹽齋鬱襯繭鹽淵獵廠 ) 更多 | 积极 | 2017-09-28 |